Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX-F03 for Sedation and Pain in Abdominal Liposuction
NCT00894699Phase 2Completed
- Sponsor
- Talphera
- Start
- Jun 2009
- Primary completion
- Sep 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sufentanil and triazolam in sedation, anxiety disorder and pain (2 arms), sponsored by Talphera. Primary endpoint: Summed Richmond Agitation Sedation at 4 hours. Started Jun 2009; status: completed.
02
Drugs
sufentaniltriazolam
03
Conditions
sedationanxiety disorderpain
Beyond the preview
Go deeper on NCT00894699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00894699.